| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | June 24, 2026 5:00 P.M. |
| Form: | S-1 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/23/2026 | $2.50 | Buy | Ladenburg Thalmann |
CAMBRIDGE, Mass., July 15, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ:DCOY), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms, today announced that stockholders elected Patricia Gauthier, MBA, LL.B., as a Class II director at the Company's 2026 Annual Meeting of Stockholders, held July 14, 2026 Ms. Gauther will serve with the Company's other two Class II directors, Rick Pierce and Jon Lieber, each of whom were re-elected at the annual meeting. "Patricia has spent her career making sure important medicines reach the peopl
DENVER, June 29, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – As the second half of 2026 begins, a series of regulatory approvals, strategic acquisitions, clinical development milestones, and financing initiatives are highlighting continued activity across the biotechnology and healthcare sectors, as companies work to expand pipelines, strengthen balance sheets, and advance toward commercialization. Universe Pharmaceuticals (NASDAQ:UPC) announced a definitive agreement to acquire Best Praise International Limited, a transaction that would add five China-based pharmaceutical patents to the company's intellectual property portfolio. The all-stock acquisition, valued at approximately $10.7
HOUSTON, June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ:DCOY) (the "Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new category of antivirals engineered to target shared viral mechanisms conserved across virus families, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor for a private investment in public equity financing (the "PIPE"), which is expected to provide approximately $3.5 million in gross proceeds at closing, before deducting placement agent's fees and other financing expenses payable by the Company. The Company intends to use the net proc
EFFECT - Decoy Therapeutics Inc. (0001615219) (Filer)
424B3 - Decoy Therapeutics Inc. (0001615219) (Filer)
8-K - Decoy Therapeutics Inc. (0001615219) (Filer)
Ladenburg Thalmann initiated coverage of Decoy Therapeutics with a rating of Buy and set a new price target of $2.50
Appointment deepens scientific leadership as Decoy advances its Designable Multi-Antiviral pipeline toward clinical developmentNEW YORK and CAMBRIDGE, Mass., May 26, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (NASDAQ:DCOY), a clinical-stage biotechnology company pioneering a new category of antivirals, today announced the appointment of Brad L. Pentelute, Ph.D., Professor of Chemistry at the Massachusetts Institute of Technology, as Chair of its Scientific Advisory Board (SAB). Dr. Pentelute is an original co-founder of Decoy and has served as a Technology Advisor since the company's inception. He is widely recognized for his foundational contributions to peptide synthesis and protein engi